Business
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
About this update from Novocure Limited
[{"type":"text","content":" ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields) as well as to encourage investigators to enter the TTFields research field.\n\nThe program includes research grants and career development awards totaling more than $1.5 million over the next three years. The grants are intended to provide a deeper understanding of the mechanisms of action of TTFields therapy and to accelerate the development of new treatment strategies to advance therapeutic options for cancer.\n\nThe research grants will include three AACR-Novocure Cancer Research Grants for independent investigators, each totaling $350,000 over three years, and one AACR-Novocure Career Development Award for Cancer Research for junior faculty members, totaling $300,000 over three years.\n\n“We are proud to continue the AACR-Novocure partnership,” said Mitch Stoller, the AACR’s Chief Philanthropic Officer. “These grant mechanisms support talented investigators and catalyze advances in TTFields research in a unique way. We look forward to welcoming another class of grantees into the program this fall.”\n\nNovocure and the AACR encourage applicants to focus their proposals on studies promoting the transition of in vitro work into in vivo systems, combination therapies involving TTFields, or translational projects bringing treatments involving TTFields into the clinic. The deadline to submit a letter of intent is May 30, 2023.\n\n“We value the opportunity to collaborate with the AACR, the world’s first and largest cancer research organization, to support research on TTFields,” said Moshe Giladi, Novocure’s Chief Science Officer. “As we aspire to make a difference in cancer, we believe TTFields therapy is a platform with game-changing potential. By deepening our understanding of the mechanisms of action behind TTFields, we hope to accelerate discovery that will allow us to help more patients around the world.”\n\nTo apply for the AACR-Novocure Grants for Tumor Treating Fields Research, visit www.aacr.org/funding.\n\nAbout Tumor Treating Fields Therapy\n\nTumor Treating Fields (TTFields) are electric field...